158 related articles for article (PubMed ID: 18245477)
21. Clinical and pathologic aspects of basal-like breast cancers.
Fadare O; Tavassoli FA
Nat Clin Pract Oncol; 2008 Mar; 5(3):149-59. PubMed ID: 18212769
[TBL] [Abstract][Full Text] [Related]
22. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
23. Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes.
Wennmalm K; Calza S; Ploner A; Hall P; Bjöhle J; Klaar S; Smeds J; Pawitan Y; Bergh J
Genes Chromosomes Cancer; 2007 Jan; 46(1):87-97. PubMed ID: 17044045
[TBL] [Abstract][Full Text] [Related]
24. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer stratification from analysis of micro-array data of micro-dissected specimens.
Alexe G; Dalgin GS; Scanfeld D; Tamayo P; Mesirov JP; Ganesan S; Delisi C; Bhanot G
Genome Inform; 2007; 18():130-40. PubMed ID: 18546481
[TBL] [Abstract][Full Text] [Related]
26. International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'.
Tavtigian SV; Pierotti MA; Børresen-Dale AL
Breast Cancer Res; 2006; 8(6):303. PubMed ID: 17096863
[TBL] [Abstract][Full Text] [Related]
27. Presenting features of breast cancer differ by molecular subtype.
Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
[TBL] [Abstract][Full Text] [Related]
28. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
Huber KE; Carey LA; Wazer DE
Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
[TBL] [Abstract][Full Text] [Related]
30. [Has the time arrived for gene expression use at the bedside?].
D'Hondt V; Piccart M; Sotiriou C
Bull Cancer; 2008 Mar; 95(3):336-43. PubMed ID: 18390414
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis of independent gene expression microarray datasets improves the predictability of breast cancer outcome.
Zhang Z; Chen D; Fenstermacher DA
BMC Genomics; 2007 Sep; 8():331. PubMed ID: 17883867
[TBL] [Abstract][Full Text] [Related]
32. How different are luminal A and basal breast cancers?
Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Buttarelli M; Jacquemier J; Chaffanet M; Maraninchi D; Viens P; Birnbaum D
Int J Cancer; 2009 Mar; 124(6):1338-48. PubMed ID: 19058218
[TBL] [Abstract][Full Text] [Related]
33. cDNA microarray analysis of inflammatory breast cancer signatures.
Laere SJ; Vermeulen PB; Dirix LY
Methods Mol Biol; 2009; 512():71-98. PubMed ID: 19347274
[TBL] [Abstract][Full Text] [Related]
34. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
35. Prediction of lymph node metastasis by gene expression profiling in patients with primary resected lung cancer.
Moriya Y; Iyoda A; Kasai Y; Sugimoto T; Hashida J; Nimura Y; Kato M; Takiguchi M; Fujisawa T; Seki N; Yoshino I
Lung Cancer; 2009 Apr; 64(1):86-91. PubMed ID: 18930562
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
van Gils W; Lodder EM; Mensink HW; Kiliç E; Naus NC; Brüggenwirth HT; van Ijcken W; Paridaens D; Luyten GP; de Klein A
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4254-62. PubMed ID: 18552379
[TBL] [Abstract][Full Text] [Related]
37. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
38. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
Voduc D; Nielsen TO; Cheang MC; Foulkes WD
Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic signatures in breast cancer.
Fu J; Jeffrey SS
Mol Biosyst; 2007 Jul; 3(7):466-72. PubMed ID: 17579771
[TBL] [Abstract][Full Text] [Related]
40. Copy number alterations that predict metastatic capability of human breast cancer.
Zhang Y; Martens JW; Yu JX; Jiang J; Sieuwerts AM; Smid M; Klijn JG; Wang Y; Foekens JA
Cancer Res; 2009 May; 69(9):3795-801. PubMed ID: 19336569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
